Eli Lilly and Company (LLY) vs S&P 500: Which Is the Better Investment?

Quick Answer

For investors deciding between Eli Lilly and Company (LLY) and the broader S&P 500 index (typically accessed via ETFs like SPY or VOO), the choice comes down to your risk tolerance and portfolio goals. Over the last decade, LLY has vastly outperformed the S&P 500, delivering annualized returns of over 32% compared to the index's 15% SPY vs LLY: Performance Charts & Full Comparison. However, this outperformance comes with significantly higher volatility and single-stock concentration risk.

The S&P 500 remains the superior choice for a foundational, core portfolio holding due to its inherent diversification, low fees, and lower drawdown risk. Conversely, LLY is an exceptional "satellite" investment for growth-oriented investors looking to generate alpha. Thanks to its remarkably low correlation to the broader market Does Eli Lilly Stock Actually Diversify Your Portfolio? | Trefis, LLY acts as a genuine portfolio diversifier while offering exposure to the booming GLP-1 weight-loss and diabetes markets.

Current Stock Price & Valuation

As of July 2026, Eli Lilly has firmly established itself as a mega-cap pharmaceutical juggernaut. The market is currently pricing in substantial future growth, driven by its dominant incretin franchise.

While a P/E ratio of 41.8 is more than double that of peers like Pfizer (18.6) What Lilly’s Peer-Beating Numbers Cost You | Trefis, it is supported by blistering fundamentals. LLY's LTM revenue growth sits at 47% What Lilly’s Peer-Beating Numbers Cost You | Trefis, and analysts project earnings growth of 46.4% for the full year 2026 Eli Lilly’s Record Run and Reset Valuation | Investing.com.

Detailed Analysis

Historical Returns Comparison

Eli Lilly has been a generational wealth compounder. Over the past 10 years, LLY has generated an annualized return of 33.14%, completely eclipsing the S&P 500's 15.28% annualized return over the same period LLY vs SPY: Performance Charts & Full Comparison | PortfoliosLab.

Looking at the medium term, LLY's 5-year annualized return is 36.50%, compared to 12.88% for the S&P 500 LLY vs SPY: Performance Charts & Full Comparison | PortfoliosLab. Over the trailing 1-year period ending July 2026, LLY surged over 50%, while the S&P 500 returned approximately 20% Does Eli Lilly Stock Actually Diversify Your Portfolio? | Trefis, LLY vs SPY: Performance Charts & Full Comparison | PortfoliosLab.

Volatility and Risk

Higher returns demand higher risk tolerance. LLY's 1-year trailing volatility is 35.77%, nearly triple the S&P 500's 12.78% LLY vs SPY: Performance Charts & Full Comparison | PortfoliosLab.

When markets turn sour, LLY can experience steeper drops. Over the past year, LLY's maximum drawdown was -23.18%, compared to just -8.88% for the S&P 500 LLY vs SPY: Performance Charts & Full Comparison | PortfoliosLab. However, on a risk-adjusted basis, LLY still wins. Its Sharpe ratio (return earned above the risk-free rate per unit of volatility) is 1.72, edging out the S&P 500's 1.62 LLY vs SPY: Performance Charts & Full Comparison | PortfoliosLab.

Diversification Benefits and Concentration Risk

One of the most compelling reasons to own LLY alongside an S&P 500 index fund is its low correlation to the broader market. Over the past five years, LLY's correlation to the S&P 500 was just 0.31, and over the past year, it dropped to an astonishingly low 0.08 Does Eli Lilly Stock Actually Diversify Your Portfolio? | Trefis, LLY vs SPY: Performance Charts & Full Comparison | PortfoliosLab. This means LLY marches to the beat of its own drum—specifically, clinical trial results and FDA approvals—making it a genuine portfolio diversifier.

However, buying LLY exposes you to severe concentration risk. The S&P 500 spreads your bet across 500 of the largest U.S. companies. With LLY, your capital is tied to a single management team and a specific pipeline of drugs.

Fees and Tax Efficiency

Investing in the S&P 500 via ETFs like VOO or SPY incurs a small expense ratio (typically 0.03% to 0.09% annually). Buying LLY stock directly incurs zero ongoing management fees.

From a tax perspective, S&P 500 ETFs are highly tax-efficient due to low turnover. Individual stocks like LLY are also tax-efficient if you buy and hold them for years, allowing capital gains to compound tax-deferred. However, if LLY's high volatility tempts you to trade in and out of the stock, you will trigger short-term capital gains taxes, which can severely drag down your net returns.

Bull Case

The bull thesis for Eli Lilly rests on its absolute dominance in the obesity and diabetes care markets. In Q1 2026, total revenue grew 56% year-over-year, prompting management to raise full-year 2026 revenue guidance to $85 billion Does Eli Lilly Stock Actually Diversify Your Portfolio? | Trefis.

The company's GLP-1 medications, Mounjaro and Zepbound, continue to see insatiable demand. Furthermore, the recent launch of Foundayo, a new oral GLP-1 for weight management, expands their total addressable market by offering a non-injectable alternative Does Eli Lilly Stock Actually Diversify Your Portfolio? | Trefis. Analysts project revenue growth of 30.8% in 2026 and 16.5% in 2027 Eli Lilly’s Record Run and Reset Valuation | Investing.com, proving that LLY's growth engine is far from stalling.

Bear Case

The primary risk for LLY is its valuation and reliance on a single franchise. At 41.8 times earnings What Lilly’s Peer-Beating Numbers Cost You | Trefis, the stock is priced for perfection. Any manufacturing constraints, safety concerns, or weaker-than-expected demand for its weight-loss drugs could trigger a severe multiple compression Eli Lilly’s Record Run and Reset Valuation | Investing.com.

Furthermore, pricing power is waning. U.S. prices for their treatments fell about 10% year-over-year recently, and management expects a price headwind in the low-to-mid teens for full-year 2026 Does Eli Lilly Stock Actually Diversify Your Portfolio? | Trefis. While volume is currently outrunning these price cuts, increasing competition from rivals like Novo Nordisk and emerging biotech firms could eventually erode LLY's market share.

Key Metrics Summary

Metric (As of July 2026)Eli Lilly (LLY)S&P 500 (SPY)
1-Year Return~61.20%~20.57%
5-Year Annualized Return36.50%12.88%
10-Year Annualized Return33.14%15.28%
1-Year Volatility35.77%12.78%
1-Year Max Drawdown-23.18%-8.88%
Sharpe Ratio1.721.62
P/E Ratio41.8~23.0

Data sourced from PortfoliosLab and Trefis. LLY vs SPY: Performance Charts & Full Comparison | PortfoliosLab, What Lilly’s Peer-Beating Numbers Cost You | Trefis.

Frequently Asked Questions

Is Eli Lilly too expensive to buy right now?

At a P/E of 41.8, LLY trades at a significant premium to the broader market and its healthcare peers. However, this premium is justified by its 46.4% projected earnings growth for 2026 Eli Lilly’s Record Run and Reset Valuation | Investing.com. It is expensive for a value investor, but reasonably priced for a hyper-growth stock.

Does owning LLY and the S&P 500 overlap too much?

No. In fact, LLY is an excellent diversifier. Over the past year, the correlation between LLY and the S&P 500 was just 0.08 LLY vs SPY: Performance Charts & Full Comparison | PortfoliosLab. LLY's price movements are driven by its specific drug pipeline and FDA approvals, not macroeconomic trends that drive the broader index.

What happens to LLY if weight-loss drug prices drop?

Prices are already dropping—U.S. prices fell roughly 10% year-over-year Does Eli Lilly Stock Actually Diversify Your Portfolio? | Trefis. However, LLY is making up for this through massive volume increases. As long as patient adoption outpaces price compression, LLY's revenue will continue to grow.

Which is better for a retirement account?

The S&P 500 is better as the core holding of a retirement account due to its diversification and lower drawdown risk. LLY is better utilized as a smaller, satellite position to boost overall portfolio returns.

Final Verdict

Is LLY a better investment than the S&P 500?

If we are measuring purely by historical returns and future growth potential, Eli Lilly (LLY) is the better investment. It has crushed the S&P 500 over every meaningful time horizon and possesses a near-monopoly in one of the most lucrative pharmaceutical markets in history.

However, if we measure by risk-adjusted safety and capital preservation, the S&P 500 wins.

The Recommendation: Do not choose just one. The S&P 500 should form the bedrock of your portfolio (70-80% of equity allocation). Because LLY has a remarkably low correlation to the S&P 500 (0.08) LLY vs SPY: Performance Charts & Full Comparison | PortfoliosLab, adding it as a 5-10% satellite position provides a mathematically sound way to increase your portfolio's overall return potential without simply doubling down on the exact same macroeconomic risks inherent in the index.

Ready to Analyze Your Next Investment?

Get a free AI-powered fair value analysis on any stock. See intrinsic value, margin of safety, and institutional-grade risk metrics in seconds. No credit card required.

Want full access to our institutional research tools? Explore Invest Daily Pro.

Put This Into Practice

You're learning portfolio theory. See how your actual portfolio measures up.

Upload your holdings and get instant diagnostics: concentration risk, correlation analysis, sector drift, factor exposures, and a rebalancing plan.

Watch: Related Videos

from Invest Daily
Watch: I Built an AI That Values Any Stock in 30 Seconds (Full Demo)
YouTube
Watch: $3 TRILLION Gone in One Day… What Happens to Stocks This Week?
YouTube

Get This Analysis in Your Inbox Every Morning

Get our daily market briefing with institutional-grade analysis, key developments, and actionable strategy - delivered before the opening bell.